Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
B cells are attracting increasing attention in the pathogenesis of multiple sclerosis (MS). B cell-targeted therapies with monoclonal antibodies or plasmapheresis have been shown to be successful in a subset of patients. Via Krishan Maggon 
Scoop.it!
Original Article from The New England Journal of Medicine — B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis (@lodaox @MustStopMS #Rituximab reduced relapses in half in Phase II trial in #MS.
RESULTS As compared with patients who received placebo, patients who received rituximab had reduced counts of total gadolinium-enhancing lesions at weeks 12, 16, 20, and 24 (P<0.001) and of total new gadolinium-enhancing lesions over the same period (P<0.001); these results were sustained for 48 weeks (P<0.001). As compared with patients in the placebo group, the proportion of patients in the rituximab group with relapses was significantly reduced at week 24 (14.5% vs. 34.3%, P=0.02) and week 48 (20.3% vs. 40.0%, P=0.04). More patients in the rituximab group than in the placebo group had adverse events within 24 hours after the first infusion, most of which were mild-to-moderate events; after the second infusion, the numbers of events were similar in the two groups. Full Text of Results... CONCLUSIONS A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The data provide evidence of B-cell involvement in the pathophysiology of relapsing–remitting multiple sclerosis. (ClinicalTrials.gov number,NCT00097188.) Via Krishan Maggon
|
Scoop.it!
PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world. Via Krishan Maggon
Krishan Maggon 's curator insight,
November 21, 2014 4:03 AM
Uptake and Presentation of Myelin Basic Protein by Normal Human B CellsMarie Klinge Brimnes, Bjarke Endel Hansen, Leif Kofoed Nielsen, Morten Hanefeld Dziegiel, Claus Henrik Nielsen mail Published: November 17, 2014DOI: 10.1371/journal.pone.0113388
|
Acta Neuropathol Commun. 2014 Sep 16;2:138. doi: 10.1186/s40478-014-0138-2.Categorization of multiple sclerosis relapse subtypes by B cell profiling in the blood.Hohmann C, Milles B, Schinke M, Schroeter M, Ulzheimer J, Kraft P, Kleinschnitz C, Lehmann PV, Kuerten S.
Acta Neuropathologica Communications 2014, 2:138 doi:10.1186/s40478-014-0138-2
The electronic version of this article is the complete one and can be found online at:http://www.actaneurocomms.org/content/2/1/138
Received:17 July 2014Accepted:5 September 2014Published:16 September 2014
© 2014 Hohmann et al.; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.